Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Accumulated Expenses (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Accumulated Expenses data on record, last reported at $12.8 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 4.99% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $12.8 million, down 4.99%, while the annual FY2025 figure was $12.8 million, 4.99% down from the prior year.
  • Accumulated Expenses reached $12.8 million in Q4 2025 per VRCA's latest filing, up from $12.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $18.9 million in Q3 2024 and bottomed at $250000.0 in Q4 2021.
  • Average Accumulated Expenses over 5 years is $6.6 million, with a median of $2.4 million recorded in 2022.
  • The widest YoY moves for Accumulated Expenses: up 890.71% in 2023, down 53.77% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $250000.0 in 2021, then skyrocketed by 459.6% to $1.4 million in 2022, then surged by 890.71% to $13.9 million in 2023, then fell by 2.52% to $13.5 million in 2024, then fell by 4.99% to $12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $12.8 million in Q4 2025, $12.6 million in Q3 2025, and $1.8 million in Q2 2025.